Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KRAS G12C (ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRAS G12C mutation

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor

Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

The consensus price target hints at a 45.4% upside potential for Revolution Medicines, Inc. (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 31.9% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants David Arrington - SVP of IR and Corporate Affairs Mark Goldsmith - Chairman and CEO Jack Anders - SVP, Finance and Principal Accounting Officer Steve Kelsey - President, Research and Development Conference Call Participants Marc Frahm - Cowen & Company Alec Stranahan - Bank of America Jonathan Chang - SVB Securities Neil Carnahan - Stifel Noah Eisenberg - JPMorgan Chase Operator Good day. My name is Christie, and I'll be your conference facilitator today.

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q2 2022 Results - Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates

First two RAS(ON) Inhibitor drug candidates advance into clinical development

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, August 9, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a conference call and webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

Underwriters' full exercise of option brings gross proceeds to $264.5 million Underwriters' full exercise of option brings gross proceeds to $264.5 million

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines Inc (NASDAQ: RVMD) shares are trading lower by 11.25% to $21.82 Wednesday morning after the company announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of $20.00 per share. Revolution Medicines says the .

Revolution Medicines Stock Is Getting Hammered: Here's Why

REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be $230.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on July 22, 2022, subject to customary closing conditions.

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

Board composition evolves as company's development pipeline matures Board composition evolves as company's development pipeline matures

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRAS G12 mutations

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?

REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a live fireside chat at the event.

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants David Errington - Senior Vice President of Investor Relations & Corporate Affairs Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Finance Conference Call Participants Marc Frahm - Cowen & Company Michael Smith - Guggenheim Christopher Zap - Goldman Sachs Jonathan Chang - SVB Leerink Operator Good day. My name is Katherine, and I'll be your conference facilitator today.

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q1 2022 Results - Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates

Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

Asana

Ford Motor Company

GameStop

Eastman Kodak

Oric Pharmaceuticals

SoFi Technologies

Here are seven stocks that have recently seen large amounts of insider purchases: Asana (NYSE:ASAN) Ford (NYSE:F) GameStop (NYSE:GME) Eastman Kodak (NYSE:KODK) Oric Pharmaceuticals (NASDAQ:ORIC) Revolution Medicines (NASDAQ:RVMD) Sofi Technologies (NASDAQ:SOFI) The post 7 Stocks That Insiders Are Buying Now. Should You?

7 Stocks That Insiders Are Buying Now. Should You?

JELD-WEN Hld

Qualtrics International

Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain.

Insiders Buy More Than $19M Of 3 Stocks

Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as Presentations in “Chemistry to the Clinic” and “Challenging Targets” Sessions and Pediatric Cancer Working Group Town Hall Meeting Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as Presentations in “Chemistry to the Clinic” and “Challenging Targets” Sessions and Pediatric Cancer Working Group Town Hall Meeting

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q4 2021 Results - Earnings Call Transcript

RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time

News for Revolution Medicines Stock (RVMD)